Approaching a New Age in Duchenne Muscular Dystrophy Treatment

Research output: Contribution to journalArticle

Abstract

Duchenne muscular dystrophy is the most common and severe form of muscular dystrophy. The cornerstones of current treatment include corticosteroids for skeletal muscle weakness, afterload reduction for cardiomyopathy, and noninvasive ventilation for respiratory failure. With these interventions, patients are walking and living longer. However, the current status is still far from adequate. Increased private and federal funding of studies in Duchenne muscular dystrophy has led to a large number of novel agents with propitious therapeutic potential. These include agents that modify dystrophin expression, increase muscle growth and regeneration, and modulate inflammatory responses. Many of these agents are already in clinical trials. Challenges to the development of additional novel therapeutics exist, including lack of validated animal models and lack of adequate biomarkers as surrogate endpoints. However, these challenges are not insurmountable and the next decade will likely see meaningful, new treatment options introduced into the clinical care of patients with Duchenne muscular dystrophy.

Original languageEnglish (US)
Pages (from-to)583-591
Number of pages9
JournalNeurotherapeutics
Volume5
Issue number4
DOIs
StatePublished - Oct 2008

Fingerprint

Duchenne Muscular Dystrophy
Biomarkers
Noninvasive Ventilation
Dystrophin
Muscular Dystrophies
Muscle Weakness
Therapeutics
Cardiomyopathies
Respiratory Insufficiency
Walking
Regeneration
Patient Care
Adrenal Cortex Hormones
Skeletal Muscle
Animal Models
Clinical Trials
Muscles
Growth

Keywords

  • clinical trials
  • Duchenne
  • gene therapy
  • muscular dystrophy
  • myostatin
  • therapeutics

ASJC Scopus subject areas

  • Pharmacology (medical)
  • Clinical Neurology
  • Pharmacology

Cite this

Approaching a New Age in Duchenne Muscular Dystrophy Treatment. / Wagner, Kathryn Rae.

In: Neurotherapeutics, Vol. 5, No. 4, 10.2008, p. 583-591.

Research output: Contribution to journalArticle

@article{794912b52efe4c0091be2e9693e37746,
title = "Approaching a New Age in Duchenne Muscular Dystrophy Treatment",
abstract = "Duchenne muscular dystrophy is the most common and severe form of muscular dystrophy. The cornerstones of current treatment include corticosteroids for skeletal muscle weakness, afterload reduction for cardiomyopathy, and noninvasive ventilation for respiratory failure. With these interventions, patients are walking and living longer. However, the current status is still far from adequate. Increased private and federal funding of studies in Duchenne muscular dystrophy has led to a large number of novel agents with propitious therapeutic potential. These include agents that modify dystrophin expression, increase muscle growth and regeneration, and modulate inflammatory responses. Many of these agents are already in clinical trials. Challenges to the development of additional novel therapeutics exist, including lack of validated animal models and lack of adequate biomarkers as surrogate endpoints. However, these challenges are not insurmountable and the next decade will likely see meaningful, new treatment options introduced into the clinical care of patients with Duchenne muscular dystrophy.",
keywords = "clinical trials, Duchenne, gene therapy, muscular dystrophy, myostatin, therapeutics",
author = "Wagner, {Kathryn Rae}",
year = "2008",
month = "10",
doi = "10.1016/j.nurt.2008.08.013",
language = "English (US)",
volume = "5",
pages = "583--591",
journal = "Neurotherapeutics",
issn = "1933-7213",
publisher = "Springer New York",
number = "4",

}

TY - JOUR

T1 - Approaching a New Age in Duchenne Muscular Dystrophy Treatment

AU - Wagner, Kathryn Rae

PY - 2008/10

Y1 - 2008/10

N2 - Duchenne muscular dystrophy is the most common and severe form of muscular dystrophy. The cornerstones of current treatment include corticosteroids for skeletal muscle weakness, afterload reduction for cardiomyopathy, and noninvasive ventilation for respiratory failure. With these interventions, patients are walking and living longer. However, the current status is still far from adequate. Increased private and federal funding of studies in Duchenne muscular dystrophy has led to a large number of novel agents with propitious therapeutic potential. These include agents that modify dystrophin expression, increase muscle growth and regeneration, and modulate inflammatory responses. Many of these agents are already in clinical trials. Challenges to the development of additional novel therapeutics exist, including lack of validated animal models and lack of adequate biomarkers as surrogate endpoints. However, these challenges are not insurmountable and the next decade will likely see meaningful, new treatment options introduced into the clinical care of patients with Duchenne muscular dystrophy.

AB - Duchenne muscular dystrophy is the most common and severe form of muscular dystrophy. The cornerstones of current treatment include corticosteroids for skeletal muscle weakness, afterload reduction for cardiomyopathy, and noninvasive ventilation for respiratory failure. With these interventions, patients are walking and living longer. However, the current status is still far from adequate. Increased private and federal funding of studies in Duchenne muscular dystrophy has led to a large number of novel agents with propitious therapeutic potential. These include agents that modify dystrophin expression, increase muscle growth and regeneration, and modulate inflammatory responses. Many of these agents are already in clinical trials. Challenges to the development of additional novel therapeutics exist, including lack of validated animal models and lack of adequate biomarkers as surrogate endpoints. However, these challenges are not insurmountable and the next decade will likely see meaningful, new treatment options introduced into the clinical care of patients with Duchenne muscular dystrophy.

KW - clinical trials

KW - Duchenne

KW - gene therapy

KW - muscular dystrophy

KW - myostatin

KW - therapeutics

UR - http://www.scopus.com/inward/record.url?scp=53049083626&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=53049083626&partnerID=8YFLogxK

U2 - 10.1016/j.nurt.2008.08.013

DO - 10.1016/j.nurt.2008.08.013

M3 - Article

C2 - 19019310

AN - SCOPUS:53049083626

VL - 5

SP - 583

EP - 591

JO - Neurotherapeutics

JF - Neurotherapeutics

SN - 1933-7213

IS - 4

ER -